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ABSTRACT
Mammalian C to U RNA ismediated byAPOBEC1, the catalytic deaminase, together with RNAbinding cofactors (including
A1CF and RBM47) whose relative physiological requirements are unresolved. Although A1CF complements APOBEC1 for
in vitro RNA editing, A1cf–/– mice exhibited no change in apolipoproteinB (apoB) RNA editing, while Rbm47mutant mice
exhibited impaired intestinal RNA editing of apoB as well as other targets. Herewe examined the role of A1CF and RBM47
in adult mouse liver and intestine, following deletion of either one or both gene products and also following forced (liver or
intestinal) transgenic A1CF expression. There were minimal changes in hepatic and intestinal apoB RNA editing in A1cf–/–
mice and no changes in either liver- or intestine-specific A1CF transgenic mice. Rbm47 liver-specific knockout (Rbm47LKO)
mice demonstrated reduced editing in a subset (11 of 20) of RNA targets, including apoB. By contrast, apoB RNA editing
was virtually eliminated (<6% activity) in intestine-specific (Rbm47IKO) mice with only five of 53 targets exhibiting C-to-U
RNA editing. Double knockout ofA1cf and Rbm47 in liver (ARLKO) eliminated apoB RNA editing and reduced editing in the
majority of other targets, with no changes following adenoviral APOBEC1 administration. Intestinal double knockout mice
(ARIKO) demonstrated further reduced editing (<10% activity) in four of five of the residual APOBEC1 targets identified in
ARIKOmice. These data suggest that A1CF and RBM47 each function independently, yet interact in a tissue-specific man-
ner, to regulate the activity and site selection of APOBEC1 dependent C-to-U RNA editing.
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INTRODUCTION
Mammalian RNA editing encompasses a process in which
select sequences within the original genomic template are
enzymatically altered to produce a change in the corre-
sponding RNA transcript (for review, see Gagnidze et al.
2018). By far the most prevalent form of RNA editing is
adenosine to inosine deamination (A-to-I), which ismediat-
ed bymembers of the family of adenosine deaminases act-
ing on RNA (ADARs) (for review, see Nishikura 2010;
Keegan et al. 2017). ADAR-mediated RNAediting requires
optimal configuration of sites within a double-stranded
RNA substrate, most typically residing within intronic
or intergenic regions enriched in Alu repeats (Nishikura
2010). The other, less prevalent form of RNA editing in-
volves cytidine to uridine deamination (C-to-U) of single-
strand RNA substrates, which is mediated by APOBEC1,
and was first described 30 yr ago as the molecular mecha-
nism underlying the tissue-specific production of two
distinct isoforms of the lipid transport protein, apolipopro-
teinB (apoB), from the liver and small intestine (Chen et al.
1987; Powell et al. 1987). Genetic deletion and rescue ex-
periments have demonstrated that the catalytic deami-
nase, APOBEC1, is absolutely required for apoB C-to-U
RNA editing (Hirano et al. 1996; Nakamuta et al. 1996),
but those experiments also revealed that additional fac-
tor(s) are required since APOBEC1 alone was insufficient
to mediate C-to-U RNA editing on synthetic apoB RNA
templates (Driscoll et al. 1993; Sowden et al. 1996b; Anant
et al. 2003).
In 2000, two groups simultaneously reported the identi-
fication of a plausible complementation factor, APOBEC1
complementation factor (A1CF), demonstrating that a two-
component system containing recombinant A1CF and
APOBEC1 alone was sufficient for efficient C-to-U RNA
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editing of apoB RNA in vitro (Lellek et al. 2000; Mehta et al.
2000). However, formal evidence of the role and requisite
physiological functions for A1CF in vivo, including its role
in C-to-U RNA editing, has been challenging to elucidate
and those efforts have yielded somewhat conflicting re-
sults. Earlier studies demonstrated early embryonic lethal-
ity in germline A1cf−/− mice with null embryos failing to
implant at E3.5d (Blanc et al. 2005). However, heterozy-
gous A1cf+/−mice were viable and exhibited defective liv-
er regeneration following partial hepatectomy, but no
change in intestinal apoB RNA editing and showed, if any-
thing, a subtle increase in hepatic apoB RNA editing (Blanc
et al. 2010). More recently, another line of A1cf−/− mice
was reported, that used a different gene targeting strat-
egy, and bypassed the early embryonic lethality reported
with the first line (Snyder et al. 2017). Those A1cf−/−
mice were viable as adults, with no overt growth pheno-
type in either liver or intestine and exhibited no change
in either apoB RNA editing or in several other candidate
RNAs that were identified from reports of a range of
APOBEC1 targets of C-to-U editing (Rosenberg et al.
2011; Blanc et al. 2014). Those findings in adult A1cf−/−
mice (Snyder et al. 2017) suggested that A1CF is dispensa-
ble for apoB RNA editing and raised the possibility that
A1CF may not participate in regulating C-to-U RNA edit-
ing activity of other physiological targets.
An alternative candidate complementation factor,
RBM47, was identified in a screen of genes in foregut en-
doderm (Loebel et al. 2011), and a role in apoB RNA edit-
ing emerged with the discovery that gene-trap Rbm47
mutant mice exhibited prenatal lethality with surviving
pups exhibiting defective C-to-U editing of intestinal
apoB RNA and several other targets (Fossat et al. 2014).
In particular, based on the loss of C-to-U RNA editing ac-
tivity in the surviving Rbm47 mutant pups, we wondered
what functions might be impaired in adult Rbm47 null
mice where conditional targeting approaches might by-
pass the severe perinatal, developmental defects?
Here we examined the role of A1CF and of RBM47 in
physiological, tissue-specific regulation of C-to-U RNA ed-
iting, both individually and in combination, in order to ex-
amine the range of target specificity and activity in vivo for
each of these potential complementation factors. The find-
ings suggest a model in which both A1CF and RBM47 ex-
hibit distinctive, tissue-specific functions that together
modulate APOBEC1 dependent RNA editing site selec-
tion and activity.
RESULTS
Subtle changes in apoB RNA editing following A1CF
deletion and transgenic A1CF overexpression
We replicated the recent findings (Snyder et al. 2017) that
A1cf−/− mice show no A1CF protein expression in liver
(Fig. 1A,B) with only minor alterations in apoB RNA editing
(65% vs. 53%, Fig. 1C) and no change in the ratio of
apoB100 vs. apoB48 protein products (Fig. 1D). There
was a small (albeit statistically significant) increase in
apoB RNA editing (84%, Fig. 1C), with no change in hepat-
ic apoB100/48 ratio (Fig. 1E) with liver-transgenic A1CF
overexpression (approximately fourfold overexpression,
Fig. 1F). Since prior studies have shown that overexpres-
sion of APOBEC1 results in promiscuous editing of apoB
RNA, beyond the canonical site (Sowden et al. 1996a;
Yamanaka et al. 1996), we examined the impact of adeno-
viral APOBEC1 (Ad-A1) overexpression in either A1cf−/−
mice deletion or with liver transgenic A1CF overexpres-
sion. Those findings revealed increased RNA editing at
the canonical site (6666) in all genotypes but generally de-
creased or absent editing at downstream sites in both
transgenic A1cf and A1cf−/− mice (Fig. 1G).
We extended those findings in small intestine, compar-
ing A1cf−/− mice to those with intestinal transgenic A1CF
overexpression (approximately fourfold overexpression,
Fig. 2A). We observed no alteration in canonical site edit-
ing of apoB RNA by genotype but again observed de-
creased editing at downstream sites in both transgenic
A1CF and A1cf−/−mice (Fig. 2B). Taken together, the find-
ings suggest that basal hepatic apoB RNA editing at the
canonical site exhibits minor changes over a range of
A1CF expression. Under conditions of forced APOBEC1
overexpression, all genotypes exhibited virtually 100%
RNA editing at the canonical site with subtle alterations
in editing activity at downstream sites in the setting of ei-
ther loss of A1CF or with transgenic A1CF overexpression.
By contrast, there was no change in intestinal apoB RNA
editing activity (versus WT) at the canonical site in either
transgenic A1CF or A1cf−/− mice.
Tissue-specific Rbm47 deletion differentially impairs
apoB RNA editing in liver and intestine
Earlier observations in Rbm47 mutant mice demonstrated
prenatal lethality (Fossat et al. 2014), making it challenging
to understand the role of RBM47 in RNA editing in adult
animals. This is an important consideration in examining
apoB RNA editing activity, since work has demonstrated
that apoB RNA editing is developmentally regulated in a
tissue-specific manner in rodents and other mammals, in-
cluding humans (Teng et al. 1990a,b; Inui et al. 1992).
Accordingly, we generated conditional Rbm47 floxed
mice (Fig. 3A and Methods) and crossed them into either
Albumin-Cre (Jax) or Villin-Cre (Jax) transgenic mice to
generate liver-specific (Rbm47LKO, Fig. 3B,C) and intes-
tine-specific (Rbm47IKO, Fig. 3D) mice, respectively, both
of which were viable as adults. We then examined apoB
RNA editing in the respective tissues, the findings demon-
strating that hepatic apoB RNA editing in Rbm47LKO mice
was reduced (∼25% C-to-U editing at the canonical site)
A1CF and RBM47 regulate C to U RNA editing
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but not eliminated, while intestinal
apoB RNA editing was virtually elimi-
nated in Rbm47IKO mice (6% residual
activity) at the canonical site (Fig. 3E,
F). Accompanying these changes in
RNA editing activity there was a corre-
sponding increase in relative hepatic
apoB100 vs. apoB48 protein expres-
sion (Fig. 3G), with no change in he-
patic A1CF expression in Rbm47LKO
mice (Fig. 3H), suggesting that
Rbm47 deletion does not produce a
compensatory change in total A1CF
abundance.
We then examined the response to
adenoviral APOBEC1 (Ad-A1) overex-
pression in Rbm47LKO mice, the find-
ings demonstrating no change in
apoB RNA editing activity at the ca-
nonical site (6666) in Rbm47LKO mice
(Fig. 3I, ∼30% editing with Ad-A1 vs.
∼25% editing at baseline, as in Fig.
3E), suggesting that hepatic RNA ed-
iting activity is constrained even with
supplemental Apobec-1.
These findings together suggest
that RBM47 is required for intesti-
nal apoB RNA editing in adult mice,
because Rbm47 deletion essentially
eliminates editing activity. By contrast,
the findings suggest the possibility
that A1CF alone provides basal com-
plementation for hepatic APOBEC1
dependent RNA editing activity (i.e.,
in the absence of RBM47) while sug-
gesting that potential stoichiomet-
ric interactions between A1CF and
RBM47 are required to establish phys-
iologic hepatic apoB RNA editing.
Combined hepatic deletion
of A1cf and of Rbm47 eliminates
hepatic apoB RNA editing
and is partially restored
with A1CF rescue, both
in vivo and in vitro
Based on the suggestion above, we
crossed Rbm47LKO mice with A1cf−/−
mice to generate mice with combined
deletion of both genes in the liver,
referred to as ARLKO mice. As expect-
ed, those ARLKO mice demonstrated
loss of both A1CF and RBM47 in liver
(Fig. 4A), but we observed that
BA
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FIGURE 1. Alterations in hepatic A1CF expression produces only subtle changes in apoB RNA
editing. (A) Hepatic expression of A1CF in wild-type (WT) and A1cf−/−mice. Actin was used as
loading control. Molecular weights (kDa) are shown to the left. (B). Immunohistochemical
detection of A1CF in WT livers showing nuclear localization of ACF and loss in A1cf−/− livers.
(C ) Hepatic apoB RNA editing by genotype. The region of apoB sequenced spans nucleotides
6563 to 7210. The data represent the average from three to four mice per genotype. Twenty
clones were sequenced for each mouse. Positions of the edited cytidines are indicated on the
left. Every circle represents a sequenced clone. Solid circles indicate C to U editing at the spec-
ified cytidine base, position indicated on the left. In all three genotypes, C to U editing is de-
tected only at apoB canonical site C6666. Editing frequency (% edited clones at cytidine 6666)
is indicated to the right. The numbers in parentheses under each panel represent the number
of edited clones versus the total number of sequenced clones. The P-value under each panel
indicates that editing at the canonical site of ApoB is statistically significant between A1cf−/−
andWT liver; betweenA1cf−/− and A1cfTg; betweenA1cfTg andWT liver. Editing frequency at
canonical C6666 editing site as mean±SE: WT: 64±4.2; A1cf−/− 53±1.8; A1cfTg 84.5±1.8.
(D) Western blot detection of ApoB100 and ApoB48 in WT and A1cf−/− livers. Detection of
Actin is used as loading control (n=5–7 per genotype). (E) Western blot analysis of
apoB100:B48 ratio inWT and transgenic A1CF liver (n=3 per genotype). Actin is used as load-
ing control. (F ) A1CF and APOBEC1 expression in WT, A1cf−/−, and AcfTg mice injected with
adenovirus-Apobec-1. Actin is used as loading control. (G) Hyperediting profile of hepatic
ApoB RNA following adenoviral-expression of Apobec-1 in WT, A1cf−/− and A1cfTg mice.
Representative data from three to four mice per genotype. Twenty clones per mouse were se-
quenced. Positions of the edited cytidines are indicated on the left. Editing frequencies at spe-
cific cytidine positions are shown to the right.
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hepatic A1CF appeared more abundant by western blot-
ting than RBM47, an impression confirmed at the RNA lev-
el as shown by quantitative PCR (Fig. 4B). We next
examined those ARLKO mice under basal conditions
(chow fed) or following Ad-A1 administration (discussed
below) to supplement basal expression of APOBEC1
(Fig. 4A). The findings at baseline in adult ARLKOmice indi-
cate no change in total apoB mRNA abundance (Fig. 4C),
with elimination of apoB RNA editing (<1%, Table 1) and
no detectable apoB48 in liver protein extracts (Fig. 4D).
Editing activity of other targets is presented in a subse-
quent section below.
To examine the possibility that A1CF might exert an
RBM47-independent role in hepatic apoB RNA editing,
we administered adenoviral A1CF (Ad-A1CF) to ARLKO
mice. Those ARLKO mice, injected intravenously with Ad-
A1CF, expressed hepatic A1CF (Fig. 4E) and revealed par-
tial restoration of apoB RNA editing (∼6% activity, Fig. 4E).
We further examined the role of A1CF using an in vitro
RNA editing assay and a synthetic apoB RNA template
(Blanc et al. 2001) in the presence of S100 extracts pre-
pared from liver of wild-type or ARLKO mice, supplement-
ed, where indicated, with either recombinant A1CF or
RBM47 as previously described (Blanc and Davidson
2010). S100 extracts prepared from wild-type mice pro-
duced robust C-to-U editing of apoB (Fig. 4E, lane 2) while
extracts from ARLKO mice were inactive (Fig. 4F, lane 3).
However, supplementing extracts fromARLKOmicewith re-
combinant A1CF partially restored editing activity, albeit
not to the level observed in extracts from wild-type mice
(Fig. 4F, lanes 4,5 vs. lane 2). Similarly, supplementing ex-
tracts from ARLKO mice with recombinant RBM47 restored
onlymodest editing activity (Fig. 4F, lanes 6–9). Those find-
ings suggest that S100 extracts from the liver ofARLKOmice
are devoid of C-to-U RNA editing activity, but that the ad-
dition of either recombinant A1CF or RBM47 proteins
alone produces partial restoration. We confirmed observa-
tions that recombinant A1CF alone with recombinant
APOBEC1 yields robust editing activity, (Fig. 4F, lane 9),
and also that recombinant RBM47 with recombinant
APOBEC1 yielded editing activity (Fig. 4F, lane 10).
Those findings suggest that either recombinant A1CF
or RBM47 provide complementation activity to recom-
binant APOBEC1 in editing apoB RNA in vitro and sup-
port the earlier observations regarding A1CF function
(Mehta and Driscoll 2002). Previous work has suggested
that therewas no additional effect on apoBRNAediting ac-
tivity following supplementation of in vitro reactions con-
taining APOBEC1 with both RBM47 and A1CF (Fossat
et al. 2014) but we did not independently explore this
question.
Combined hepatic deletion of A1cf and of Rbm47
modifies RNA activity of a subset of targets
Based on the finding that hepatic apoB RNA editing was
reduced but not eliminated in Rbm47LKO mice, we exam-
ined C-to-U RNA editing efficiency across the range of pre-
viously identified hepatic targets (Blanc et al. 2014), in the
four genotypes (WT, A1cf−/−, Rbm47LKO, and ARLKO). The
findings show that deletion of A1cf alone failed to alter ed-
iting activity in any of 21 targets examined (Table 1). By
contrast, hepatic C-to-U RNA editing efficiency in
Rbm47LKO mice was decreased (average of 64%, range
44%–84%), but not eliminated, in 11 targets (including
apoB), unchanged in four targets (Table 1) and, to our sur-
prise, increased in four targets (Table 1). Of those four tar-
gets whose C-to-U RNA editing efficiency was increased in
Rbm47LKO mice, all showed decreased editing in ARLKO
mice (including to <1% in Cmtm6, Sh3bgrl, and Rnf128),
B
A
FIGURE 2. NeitherA1cf deletion or overexpression in intestinal trans-
genic A1CF mice alter intestinal ApoB RNA editing. (A) Intestinal
A1CF expression in WT, A1cf−/−, AcfTg and littermate controls
(WTc). Transgenic A1CF expression detected using both anti-A1CF
and anti-FLAG antibody. Detection of Actin is used as loading control.
(B) Intestinal apoB RNA editing profile. The data represent the aver-
age from three mice per genotype, 15–22 clones were sequenced
for each genotype. Solid circles identify clone with editing at the
site indicated to the left.
A1CF and RBM47 regulate C to U RNA editing
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suggesting that these particular loss-
of-function effects of hepatic Rbm47
deletion also require loss of A1CF. In
addition, there was a further subset
of targets (including Sep15, Mpeg,
and Cybb) whose editing activity was
either unchanged or only slightly de-
creased in ARLKO mice (Table 1). A
summary figure of the proposed
hierarchy for A1CF, RBM47 and the
combination (A1CF plus RBM47) in
hepatic C-to-U RNA editing is pre-
sented in Figure 4G.
Combined intestinal deletion of
both A1cf and Rbm47 eliminates
C-to-U RNA editing in the majority
of RNAs and reveals tissue-
specific roles in target selection
The findings above indicate a distinct
tissue-specific requirement for RBM47,
since hepatic apoB RNA editing was
reduced but not eliminated in
Rbm47LKO mice (Fig. 3E), while apoB
RNA editing was virtually eliminated
in Rbm47IKOmice (Fig. 3F). According-
ly, we examined the possibility that
editing at other RNA target sites was
altered in Rbm47IKO mice. The find-
ings indicate that the majority (48/53)
of targets exhibited >90% reduction
in RNA editing activity in Rbm47IKO
mice (Table 2), including four targets
(B2M, Cmtm6, Rnf128 and Sh3bgrl)
where (hepatic) RNA editing activi-
ty was found to be increased in
Rbm47LKO mice (compare data in Ta-
ble 1, vs. Table 2). While RNA editing
was reduced in the majority of targets
in Rbm47IKO mice, we identified five
targets (Cyp4v3, Kctd12, Tmbim6,
Sep15, and Bche) with significant
residual editing activity (Table 2). In or-
der to examine the impact of com-
bined loss of A1CF and RBM47 in
adult intestine, we crossed Rbm47IKO
mice with A1cf−/− mice to generate
mice with combined deletion referred
to as ARIKO mice (Fig. 5A). As expect-
ed, ARIKO mice exhibited no apoB
RNA editing at any of the previous-
ly identified sites (Fig. 5B), and no
change in total intestinal apoB
mRNA abundance was observed in
A
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FIGURE 3. Generation and characterization of conditional Rbm47 knockout mice.
(A) EndogenousmouseRbm47geneand targeting construct. Schematic illustrationof genomic
structure of Rbm47 allele containing nine exons (orange boxes). Schematic of Rbm47tm1a com-
position. (Numberedorangesboxes)Rbm47exons; (blueboxes)LacZandneocassettes; (green
triangles) FRTsites; (purple triangles) LoxPsites. FLP recombinationeliminates theLacZandneo
cassettes. Exon6 containing transcriptional start codon and sequences encodingRNA recogni-
tion motifs was targeted for Cre-dependent homologous recombination. (B) Representative
DNAelectrophoresis showinggenotypeofWTand targetedallelesusingprimersP1andP2sur-
rounding the 3′arm LoxP site. Analysis of theWT allele results in a 490 bp PCR product (lane 1)
whereas recombination at the floxed allele generates a 530 bp product (f/f) (lane 3). Cre activa-
tion resuts in the loss of exon 6, evidenced by the absence of PCR amplification (lane 5).
Molecular weights (bp) are indicated to the left. (C ) Western blot detection of RBM47 in liver
of floxed and Rbm47 liver-specific knockout (Rbm47LKO) mice with Actin used as loading con-
trol. (D) Western blot analysis of RBM47 in Rbm47IKOmice showing no detectable protein in in-
testinal nuclear extract. (E) Hepatic apoBRNAediting profile inRbm47LKOmice, representative
of three individual livers. Forty-two clones were sequenced, with each clone represented by a
circle. Solid circles indicate editing at the specified position. We examined an apoB region en-
compassingnucleotides6563–7210,witheditingonlyat thecanonicalcytidine (6666)detected.
(F ) Intestinal apoB RNA editing profile in Rbm47IKO mice. Representative distribution of RNA
editing sites from the same region (6563–7210) revealing only 2/19 clones exhibiting RNA ed-
iting. (G) Western blot analysis of hepatic apoB100 and apoB48 isoforms (three to fivemice per
genotype)withactinas loadingcontrol. (Panel to the right )QuantitationofapoB100 isoformasa
fraction of total apoB showing significant increase of apoB100 in liver of Rbm47LKO mice. (H)
Western blot analysis of RBM47 and A1CF in Rbm47LKOmice at baseline and following adeno-
viral APOBEC1overexpression. (I ) Editingandhypereditingprofile of hepatic apoBRNA follow-
ing adenoviral overexpressionof APOBEC1 in twoRbm47LKOmice. Representativedistribution
of edited sites from nucleotide 6563 to nucleotide 7210.
Blanc et al.
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any genotype (Fig. 5C). We then ex-
amined editing activity in ARIKO mice
in the five targets identified above
demonstrating residual editing activi-
ty in Rbm47IKO mice. Those findings
demonstrated decreased editing ac-
tivity in four of five targets with one
(Kctd12) exhibiting 30% C-to-U RNA
editing, despite the absence of both
A1CF and RBM47. These findings
strongly suggest that RBM47 plays a
dominant role in regulating Apobec-
1dependent RNAediting inmouse in-
testine, but also support the conclu-
sions that A1CF plays a permissive
role in a subset of targets. The one ex-
ception was C-to-U RNA editing of
Kctd12, which was uninfluenced by
the loss of either complementation
factor.
DISCUSSION
There is considerable information re-
garding the physiological regulation
of mammalian C-to-U RNA editing,
particularly for the prototype target
apoB RNA, which undergoes tissue-
specific regulation, modulated by
developmental, hormonal, and nutri-
tional cues in mouse and rat liver,
through mechanisms proposed to in-
volve regulation of the complementa-
tion factors (Teng et al. 1990a; Inui
et al. 1992, 1994; Lau et al. 1995;
Lehmann et al. 2006). In addition, in-
testinal apoB RNA editing is develop-
mentally regulated in bothmouse and
human small intestine, findings at
least partially accounted for by the
temporal patterns of APOBEC1 ex-
pression but which may also reflect al-
terations in A1CF activity (Teng et al.
1990b; Giannoni et al. 1995). These
earlier studies, coupled with findings
showing that A1CF undergoes alter-
native splicing with differential func-
tions assigned to each splice form
(Galloway et al. 2010), supported the
view that A1CF undergoes nuclear-
cytoplasmic shuttling in conjunction
with metabolically regulated, post-
translational modifications that in
turn regulate C-to-U RNA editing
(Galloway and Smith 2010). The view
B C
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FIGURE 4. Combined hepatic deletion of A1cf and Rbm47 in double knockout (ARLKO) liver
eliminates apoB RNA editing. (A) Western blot analysis of A1CF, RBM47, and APOBEC1 in liv-
ers of ARLKO mice, with or without Ad-Apobec1. Actin was used as a loading control.
(B) Quantitative PCR analysis of hepatic A1cf and Rbm47 RNAs demonstrating greater A1cf
mRNA abundance versus Rbm47 RNA. Data represents mean±SE of four to five mice per ge-
notype. (∗∗) P-value<0.01. (C ) Quantitative PCR analysis of hepatic apoB RNA, showing no dif-
ferences by genotype (mean±SE of three to four mice per genotype). (D) Western blot of
hepatic apoB protein in Rbm47LKO, A1cf−/−, andARLKOmice. Actin was used as a loading con-
trol. (E) Western blot detection of FLAG-A1CF following adenovirus A1CF administration to
ARLKOmice. The calculated percent C-to-U apoB RNA editing indicates apoB editing frequen-
cy at the canonical site C6666. Parentheses indicate number of clones containing the edited
site vs. the total number of sequenced clones. (F ) In vitro apoB RNA editing assay using liver
S100 extracts (lane 1 negative control contains primer and bovine serum albumin only) pre-
pared from either WT mice (lane 2), or from ARLKO mice (lanes 3–8), or using recombinant
(rec) APOBEC1 (lanes 9,10), supplemented where indicated with recombinant A1CF (lanes
4,5) or RBM47 (lanes 6–8). ApoB RNA editing was determined by poison primer extension
(Materials and Methods). The relative mobility of the unedited (C) and the edited (U) C6666
is indicated to the right. Representative of three independent assays. (G) Baseline hepatic ed-
iting efficiency of 3′UTR APOBEC1 RNA targets and hierarchy of RNA binding complementa-
tion factors (see Table 1 for data). Wild-type (black dots), Rbm47LKO (green dots),A1cf−/− (blue
dots), ARLKO (orange dots), and Apobec1−/− (white dots). RNAs preferentially edited by
RBM47 show decreased editing efficiency in Rbm47LKO and ARLKO and no change in A1cf−/−.
In contrast, RNAs preferentially edited by A1CF show no change in the absence of A1CF
but increased editing frequency in the absence of RBM47 and almost complete loss of editing
in the absence of both A1CF and RBM47.
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that A1CF was a necessary cofactor for C-to-U RNA editing
was radically revised with the report that Rbm47 mutant
mice exhibit virtually no intestinal apoB RNA editing and
also that a two-component system containing recombi-
nant RBM47 with recombinant APOBEC1 together cata-
lyze in vitro apoB RNA editing (Fossat et al. 2014). Those
findings, coupled with the recent report that A1cf−/−
mice exhibit no detectable alterations in C-to-U RNA edit-
ing (Snyder et al. 2017), led to the alternative suggestion
that RBM47 acts alone as the complementation factor for
APOBEC1 dependent RNA editing, and left open the
function (if any) for A1CF in vivo. The findings from this re-
port offer a more nuanced view, namely, that A1CF and
RBM47 function independently, yet interact in a tissue-
specific manner to regulate the activity and site selection
of Apobec-1 dependent C-to-U RNA editing in adult
mouse intestine and liver. Several aspects of this report
merit further discussion.
A1CF was independently identified by two groups,
through approaches based in part on RNA binding affinity
of factors purified from either baboon or rat liver that were
enriched by binding to an apoB RNA fragment flanking the
C-to-U editing site, which eventually yielded a single pro-
tein that exhibited complementation activity for in vitro
apoB RNA editing (Lellek et al. 2000; Mehta et al. 2000).
Those findings, coupled with findings that RBM47 colocal-
izes and physically interacts with both APOBEC1 and with
A1CF (Fossat et al. 2014) suggest that the in-vivo comple-
mentation activity originally assigned to A1CF may reflect
the optimal configuration of RBM47 and APOBEC1in the
context of a heteromeric, functional editosome complex,
containing A1CF (Fossat et al. 2014). By contrast, the struc-
tural and functional homology of A1CF and RBM47 likely
accounts for the ability of either pro-
tein to provide complementation
activity in a reconstituted, two compo-
nent in vitro assay (Fossat et al. 2014)
and Figure 4F. These observations al-
low us in principle to reconcile the
apparent paradox that A1CF alone
with APOBEC1 is sufficient for in vitro
RNA editing yet appears dispensa-
ble for physiological editing activity
in vivo.
Based on the finding that Rbm47
mutantmiceexhibit virtually no intesti-
nal apoB RNA editing in the surviving
animals (Fossat et al. 2014),weexpect-
ed to find that hepatic apoB RNA edit-
ing would be similarly eliminated in
Rbm47LKO mice. However, that was
not the case. We observed instead
that RNA editing was reduced but
not eliminated in Rbm47LKO mice
and that both isoforms of apoB were
readily detectable, albeit with an altered ratio reflecting
the decreased RNA editing activity. Similarly, we observed
decreased activity in 11 of 20 other targets of C-to-U RNA
editing in those Rbm47LKO mice, no change in a further
subset and an increase in yet another subset of four targets
(B2m, Cmtm6, Sh3bgrl, Rnf128, Table 1). We interpret
those findings to indicate that RBM47 provides the domi-
nant sourceof complementation activity for the11of 20 tar-
gets that exhibit decreased editing in Rbm47LKO mice,
while the subset of four targets showing increased editing
activity inRbm47LKOmicemaybepredominantly A1CFde-
pendent, as evidenced by the loss of editing activity in
ARLKOmice. The additional subset of hepatic targets dem-
onstrating ∼12%–14% residual editing activity in ARLKO
mice (Table 1) might conceivably reflect residual expres-
sion of A1CF or RBM47 within non-parenchymal cells
(Kupffer cells, stellate cells, endothelial cells, or cholangio-
cytes), which would not be amenable to Cre deletion with
the albumin promoter used in these studies, which is re-
portedly hepatocyte predominant (Postic et al. 1999).
The same caveats might be considered for the findings
with Rbm47IKOmice where a small subset of targets exhib-
ited residual editing activity, most of which were further re-
duced in ARIKOmice. Those studies were conducted using
scraped intestinal mucosa which contains >90% entero-
cytes but may also include submucosal and lamina propria
cell types, including neuronal cells. It is worth noting that
the villin promoter, used to drive intestinal Cre expression
in our studies, is reported to be confined to villus entero-
cytes and colonocytes with some expression in renal tubu-
lar cells (el Marjou et al. 2004). This cell-restricted pattern
of villin-Cre expression may be a relevant consideration
for the observations regarding RNA editing of Kctd12,
TABLE 1. C-to-U editing efficiency by genotype of hepatic 3′UTR APOBEC1 RNA targets
RNAs highlighted in blue are preferentially edited by RBM47. RNAs in green are preferentially
edited by A1CF. RNAs in orange are equally edited by both RBM47 and A1CF
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which demonstrated robust (30%) Apobec-1 dependent
editing in ARIKO mice. Kctd12 encodes a potassium chan-
nel which is known to be widely expressed in human and
mouse tissues including in intestinal neuroendocrine and
colorectal tumors as well as throughout the brain
(Resendes et al. 2004; Li et al. 2016; Suehara et al. 2018).
Thus, it is possible that Kctd12 expression in cells other
than enterocytes might account for the preserved RNA ed-
iting activity in Rbm47IKO and ARIKO mice. Nevertheless,
an alternative interpretation might also be considered,
namely that other (to be identified) complementation fac-
tors might be responsible. A further consideration is that
Apobec-1 alone may be sufficient to mediate C-to-U
RNA editing of a small subset of transcripts, as implied ear-
lier (Chester et al. 2004). Resolution of these possibilities
will require further investigation beyond the scope of the
current studies.
The tissue-specific roles of A1CF and RBM47 in RNA
editing was further supported by the finding that four he-
patic targets (B2m, Cmtm6, Sh3bgrl Rnf128) that were
edited more efficiently by A1CF in the liver (Table 1)
were edited only by RBM47 in the intestine (Table 2).
One possibility to explain this apparent discrepancy is
that the binding site(s) in those RNAs for A1CF may not
be as accessible in the intestine as in the liver, perhaps
because the folding of RNAs may be different and/or
there may be other RBPs that in turn modify access of tar-
get transcripts to A1CF. The identification of A1CF/RNA/
protein partners will require extended investigation be-
yond the focus of this study.
The proposed dominance of RBM47 in hepatic apoB
RNA editing is further supported by the observation that
hepatic A1CF appears to be expressed at higher levels
than RBM47 (Fig. 4A) while loss of A1CF alone exerts
only minor if any effect on apoB RNA editing. This may im-
ply either greater affinity or sustained occupancy with an
RBM47-apoB RNA- APOBEC1 complex compared to
an A1CF-apoB RNA-APOBEC1 complex. It is also conceiv-
able that both RBM47-Apobec-1 and A1CF-APOBEC1
complexes coexist, with RBM47-APOBEC1 complex being
more efficient in mediating RNA editing, but this specula-
tion will require formal examination and a more complete
understanding of the relativemolar distribution of each co-
factor within these complexes.
The current findings also raise the question of a broader
biological role for A1CF andRBM47 inmammalian physiol-
ogy. As noted above, our initial attempt to generate germ-
line A1cf−/− mice revealed early developmental lethality
with homozygous A1cf−/− blastocysts failing to implant at
embryonic day 3.5 (Blanc et al. 2005). A different line of
A1cf−/−mice (used in the studies reported here) employed
a distinct genomic targeting strategy (Snyder et al. 2017)
and also used sox2-Cre which is active at embryonic day
6.5 and which would bypass the early, preimplantation le-
thality observed in our studies (Blanc et al. 2005; Moore
TABLE 2. C-to-U RNA editing efficiency by genotype of
intestinal 3′UTR APOBEC1 targets
RNA Position Ref WT A1cf–/– Rbm47IKO
ApoB 8,014,860 C 94.3 94.3 5.3
Serinc1 57,235,791 G 67.3 70.3 5.9
Aldh6a1 85,772,761 G 52.9 42.4 2.9
B2m 121,978,638 C 19.2 16 0
Sep15 144,259,976 C 12.2 9.4 9.5
Cd36 17,288,955 G 87.4 77.2 14.7
Cyp4v3 46,391,931 G 25.4 25.9 53.7
Tmem30a 79,617,629 G 62.5 61.9 6.7
Cmtm6 114,658,289 C 31.6 35.4 6.5
Sh3bgrl 106,355,759 C 25 26 4.2
Rnf128 136,207,009 C 19.2 20.4 3.2
Usp25 77,116,537 C 44 48.9 0
BC013529 7,487,994 G 35.2 37.2 6.3
Ank3 69,486,962 C 7.5 9.1 0
Actr2 19,963,383 G 22.6 24.6 7.7
Rab1 20,125,336 C 22.7 22.2 0
Tmem195 38,308,269 C 36.2 40.2 9.9
Dek 47,181,166 G 6.2 5.3 0
Nr1d2 19,036,726 G 17.3 22.2 3.6
Cnih 47,395,982 G 38.4 38.5 6.3
Kctd12 103,379,573 G 33.6 29.8 17.1
1110020G09rik 9,038,469 C 6.9 5.8 1
Tmbim6 99,239,051 C 20.2 19.7 14.7
Gramd1c 43,981,376 G 44.8 41.6 7.7
App 84,954,758 G 7.5 5.5 4.5
App 84,955,113 G 24.2 23.9 2
Clic5 44,416,335 C 18.8 23.6 0
Ccny 9,315,769 G 25.3 25.3 2.9
610010O12rik 36,562,329 C 52.5 54.2 0
Ttc9c 8,885,447 G 25.6 29.4 2.9
Cyp2c65 39,168,358 C 7 9.9 0
Fmn1 113,556,683 C 22.4 24 2
Rrbp1 143,811,725 G 9.6 8.6 1.6
Skil 31,018,375 C 11.8 10.8 2.2
Bche 73,442,586 G 36 18.6 13.7
Lrba 86,586,529 C 11.4 11.7 2.3
Dpyd 119,134,596 C 23.2 23.8 1.6
Lrcc19 94,304,303 G 8.4 9.1 0
Fgl2 20,883,372 C 37.7 28.5 2.5
Yes1 32,989,151 C 21.7 20.8 0
Sult1d1 87,984,364 G 75 76.9 8.8
Slc4a4 89,668,527 C 12 16.4 1.9
mCG_2776 8,378,189 C 13 16.1 2.9
Siglec5 50,614,573 C 33.6 38.2 8
Herc2 63,486,942 C 36.4 39.6 4.4
Tmem135 96,290,044 G 35.1 40 9.9
Mcmbp 135,841,366 G 47.4 47.8 4.8
Ddx60 64,516,163 C 43.2 46.4 11
Mtmr2 13,610,423 C 26 24.2 5.4
Hprt1 50,374,459 C 12 10 4.5
Atpc11c 57,477,477 G 1.9 2.6 0
Sh3bgrl 106,356,686 C 34.3 32.6 5.2
Reps2 158,851,906 G 22.1 24.9 2
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et al. 2014). Those A1cf−/− mice were viable as adults yet
showed abnormalities in renal function, while the viable
heterozygous A1cf+/− mice from the initial knockout at-
tempts demonstrated a growth phenotype with defective
liver regeneration following partial hepatectomy (Blanc
et al. 2010). Along the same lines, the original line of mu-
tant, gene-trap Rbm47−/−mice demonstrated perinatal le-
thality with the surviving animals showing a runted
phenotype (Fossat et al. 2014). Our findings used a differ-
ent genomic targeting strategy and conditional tissue-spe-
cific deletion which again bypassed the perinatal lethality.
Whilewe observed no gross defects in liver or intestinal de-
velopment in Rbm47IKO, Rbm47LKO, or the corresponding
double knockout lines (i.e., ARIKO and ARLKOmice), we are
currently examining in more detail the possibilities of other
growth-related and metabolic phenotypes.
As a final comment, we recognize that the current find-
ings are limited to the tissue-specific impact of A1CF and
of RBM47 within the liver and small intestine but we cer-
tainly acknowledge the importance of APOBEC1 depen-
dent C-to-U RNA editing activity in other cell types as
revealed by recent studies in microglia and monocytes de-
rived from Apobec1−/− mice (Cole et al. 2017; Rayon-
Estrada et al. 2017). We envision future studies utilizing a
range of other cell-specific Cre drivers to elucidate the
role of RBM47 in those contexts also.
MATERIALS AND METHODS
Animals
Rbm47 conditional knockout animals were
generatedby in vitro fertilization ofC57BL/
6 oocytes (Washington University Mouse
Genetics Core) with sperm carrying the
Rbm47tm1a mutation (Rbm47tm2a(EUCOMM)
Wtsi) obtained from the International
Mouse Phenotyping Consortium/
European Mouse Mutant Archive
(EMMA). Offspring were then bred with
Flp-1 Tg mice (Jax# 009086) to remove
the Frt-flanked LacZ-Neo cassette (Fig.
3A). Genotyping was performed using the
following primers surrounding the 3′arm
LoxP site: Rbm47 Fwd LoxP (P1) (5′-ACT
CCT GTG ACC CCT ACA CG-3′) and
Rbm47 Rev 24157 (P2) (5′-GTA ACC CAG
GCT GGC CTA-3′), using the following
conditions: 94°C for 5 min; 94°C for 30
sec, 60°C for 45 sec, 72°C for 50 sec (35 cy-
cles); 72° C 10 min. The PCR reaction gen-
erates a 490 bp wild-type band and a 530
bp Rbm47 floxed (Rbm47f/f) band. Hetero-
zygous intercrosses resulted in viable and
fertile homozygous Rbm47f/f mice with a
normal Mendelian frequency. To generate
liver-specific knockout mice (Rbm47LKO),
Rbm47tm1a mice were crossed with Albu-
min-Cre transgenic mice (Jax# 003570).
Intestine-specific Rbm47 knockout (Rbm47IKO) were generated
by crossing Rbm47tm1a mice with transgenic villin-Cre-ERT2 mice
(el Marjou et al. 2004). Cre recombinase migration to the nuclear
compartment was induced by intraperitoneal injection of 1 mg/
100 µL tamoxifen (Sigma) 1 mg/day for 5 d (el Marjou et al.
2004). All experimental and control animals were maintained on
a C57BL/6J background.
A1cftm1b (A1cf−/−) were obtained from Jax (#005650) (Snyder
et al. 2017) and maintained on a C57BL/6NJ background. Liver
(ARLKO) and intestine (ARIKO)-specific A1cf-Rbm47 double knock-
outs were generated by breedingA1cf−/−micewith Rbm47LKO or
Rbm47IKO, respectively. Apobec-1−/−mice were maintained on a
C57BL/6J background. For hepatic overexpression of Apobec-1,
animals were injected with 6× 108 plaque-forming units of recom-
binant adenovirus encoding rat Apobec1 (Kozarsky et al. 1996).
Mice were 8–12 wk old and fed an ad libitum chow diet. All ani-
mals were treated according to the National Institutes of Health
guidelines and all protocols were approved by the Washington
University Institutional Animal Care and Use Committee.
RNA isolation, cDNA synthesis, and quantitative PCR
RNA was extracted from tissues of the indicated genotype using
TRIzol (Invitrogen) following manufacturer’s instructions. DNase-
free RNAs (RNase-Free DNase kit, Qiagen) were used for cDNA
preparation using the High Capacity cDNA Reverse Transcription
kit (Applied Biosystems). Quantitative evaluation of RNA abun-
dancewas performed using Fast SYBRGreenMasterMix (Applied
BA
D
C
FIGURE 5. Combined intestinal deletion of A1cf and Rbm47 in double knockout (ARIKO) mice
eliminates apoB RNA editing and reduces C-to-U editing activity in four of five residual targets
from Rbm47IKO mice. (A) Western blot analysis of intestinal A1CF and RBM47 in ARIKO mice.
Actin was used as a loading control. (B) Intestinal apoB RNA editing is eliminated in ARIKO
mice. Data are representative of four individual animals. Open circles represent individual
clones (total of 32 clones sequenced) in the region spanning nucleotides 6563 to 7210.
(C ) Quantitative PCR analysis of intestinal apoB RNA showing no differences by genotype,
from representative mice (n=3–4 per genotype). (D) Baseline editing efficiency of the subset
of intestine 3′UTR APOBEC1 RNA targets that revealed residual editing activity in Rbm47IKO
mice. Data are indicated as percentage of edited clones with numbers in parentheses indicat-
ing edited versus total number of sequenced clones.
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Biosystems) in a StepOne PLus Real Time PCR system instrument
(Applied Biosystems). The following primers were used: A1cf:
Fwd: 5′-GCC AGA ATC CTCG CAA TCCA-3′; Rev 5′-AGC ATA
CCT CTT CGC TTC ATC C-3′, Rbm47 Fwd: 5′-GCT TCG CCT
TTG TGG AGT ATG-3′; Rev: 5′-ATC CGA CCTGGC ATG AG-3′,
ApoB Fwd: 5′-CAC TGC CGT GGC CAA AA-3′, Rev: GCT AGA
GAG TTG GTC TGA AAA ATC CT-3′. Total mRNA abundance
was determined by normalization to Gapdh RNA level in each
sample. Primers for Gapdh are as follows: Fwd: 5′- TGTGTCCGT
CGTGGATCTGA-3′; Rev: CCTGCTTCACCACCTTCTTGA-3′.
RNA editing analysis by Sanger sequencing
Following reverse transcription, cDNA was used to amplify se-
quences containing Apobec-1-dependent editing sites previous-
ly identified in liver and small intestine (Blanc et al. 2014). PCR
amplifications were performed using AccuPrime Pfx DNA poly-
merase (Thermo Fisher Scientific). Primer sequences are available
(Blanc et al. 2014). PCR products were then gel purified using
Qiaquick Gel Extraction kit (Qiagen) and cloned using Zero
Blunt TOPOPCRCloning kit (Invitrogen) followingmanufacturer’s
recommendations. At least 20 individual clones were sequenced
at Genewiz Inc.
Amplicon sequencing
PCRproductsofApobec-1hepaticandsmall intestineRNAtargets
were concatemerized as follows. The PCR products (∼12 ng) were
treated with DNA polymerase I, Large Klenow Fragment (NEB) for
30 min at 37° C following manufacturer’s instructions. After purifi-
cation using PCR Purification kit (Qiagen), the PCR products were
ligated overnight at room temperature using a mix of T4 DNA li-
gase and T4 polynucleotide kinase in the presence of 50% PEG-
8000. Ligated products were purified using PCR Purification kit
and ligation was confirmed by running aliquot of ligation on a
1% agarose gel. Concatemerized amplicons were then submitted
for automated high-throughput DNA sequencing (Washington
University Genome Center). The results of sequencing hepatic
and intestinal amplicons are presented in Tables 1 and 2.
Protein extraction and western blotting
Total liver and scraped intestinal mucosa were homogenized as
previously described (Blanc et al. 2014). Nuclear extracts were
prepared using Glass Dounce Tissue homogenizer. Fifty milli-
grams of tissue was homogenized in 300 µL of Buffer A (25 mM
Tris pH 7.5, 50 mM KCl, 2 mM MgCl2, 1 mM EDTA, 5 mM DTT,
1× protease inhibitor [Roche], 100 mM NaF, 1 mM NaVa, 50
mM α-glycerophosphate) performing 30 strokes with pestle A fol-
lowed by 20 strokes with pestle B. The nuclear pellet was collect-
ed by centrifugation at 4000 rpm at 4°C for 10 min. The nuclei
were washed three times with Buffer A, resuspended in 80 µL of
Buffer B (25 mM Tris pH 7.5, 420 mM NaCl, 1.5 mM MgCl2, 0.5
mM EDTA, 1 mM DTT, 20% glycerol, 1× protease inhibitor) and
incubated in ice for 30 min with a regular period of 30 sec vortex.
Nuclear fraction was then collected by centrifugation 15 min at
10,000 rpm at 4°C. Fifteenmicrograms of nuclear protein were re-
solved on a SDS–PAGE, transferred to PVDF membrane and
probed with rabbit anti-A1CF antibody, rabbit anti-RBM47
(Abcam ab94638), anti-APOBEC1 (Kozarsky et al. 1996). Equal
loading was confirmed using a rabbit anti-actin antibody
(Sigma–Aldrich).
For detection of hepatic apoB isoforms, liver tissue was homog-
enized using modified RIPA buffer containing 1 M urea (Smagris
et al. 2016). Fifty milligrams of tissue were suspended in 300 µL
RIPA/urea buffer and homogenized in a bullet blender with 200
µL of 1 mm Glass Beads (Next Advance) twice for 5 min at maxi-
mum speed (speed 10) at 4°C. An additional 400 µL of RIPA/
urea buffer was added and the mixture homogenized at speed 3
for 3 min at 4°C. The Homogenates were supplemented with
one tenth of the volume with 10× detergent buffer (10% SDS,
10%NP-40) and incubated in ice for 30min, before centrifugation
15min at4°C15,000 rpm.Eightymicrogramsof extractswere then
fractionated on a 4%–20% SDS gradient gel, transferred on PVDF
membrane andprobedwith rabbit anti-apoB (1:4000). Equal load-
ing was checked using rabbit anti-actin (1:2000) antibody.
In vitro RNA editing analysis by poisoned primer
extension
A synthetic 360-nt apoB RNA (20 fmol) was incubated with liver
extracts prepared from wild-type or A1cf-Rbm47 liver-specific
double knockout (ARLKO) mice. S100 extract (100 µg) or recombi-
nant Apobec-1 (400 ng) was supplemented where indicated with
increasing amounts (50 to 200 ng) of recombinant A1CF (Blanc
et al. 2001) or recombinant mouse RBM47. Recombinant
RBM47 protein was generated by cloning Rbm47 cDNA from
mouse liver into the NdeI-XhoI sites of pTYB1 expression vector
(New England Biolabs), resulting in synthesis of a C-terminal
RBM47-intein fusion protein. RBM47 was purified as previously
described (Blanc et al. 2001). S100 extracts with or without recom-
binant proteins were incubated for 3 h at 30°C in in-vitro conver-
sion buffer (Blanc et al. 2001; Blanc and Davidson 2011).
Following incubation, RNA was phenol/chloroform extracted,
precipitated and resuspended in cDNA synthesis reaction mix.
Single-strandedDNAwas then subjected to PCR amplification us-
ing the following apoB primers: Fwd:5′-ATCTGACTGGGAGA
GACAAGTAG-3′, Rev: 5′-GCTCGCTCAGGCTATATCTGTGG
GC-3′. PCR product was then used as template in poison primer
extension as previously described (Blanc and Davidson 2011).
Extension products were separated by electrophoresis on a 7 M
urea-acrylamide gel and analyzed by autoradiography.
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